Evidence map›Paper›PMID 32308515›Full record

ArticleJournal of blood medicine2020

Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation.

Umberto Restelli, Davide Croce, Erminio Bonizzoni, Mario Marzanatti, Angelo Andreini, Marco Sorio, Cristina Tecchio, Erika Barison, Fabio Benedetti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of blood medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Umberto RestelliSchool of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.ORCID 0000-0001-6831-3044
Davide CroceSchool of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-9472-3431
Erminio BonizzoniSection of Medical Statistics and Biometry "GA Maccacaro", Department of Clinica Science and Community, University of Milan, Milan, Italy.
Mario MarzanattiSection of Medical Statistics and Biometry "GA Maccacaro", Department of Clinica Science and Community, University of Milan, Milan, Italy.
Angelo AndreiniBone Marrow Transplant Unit- Hematology, University of Verona, Verona, Italy.ORCID 0000-0001-7562-3577
Marco SorioBone Marrow Transplant Unit- Hematology, University of Verona, Verona, Italy.ORCID 0000-0001-9155-6618
Cristina TecchioBone Marrow Transplant Unit- Hematology, University of Verona, Verona, Italy.
Erika BarisonBone Marrow Transplant Unit- Hematology, University of Verona, Verona, Italy.
Fabio BenedettiBone Marrow Transplant Unit- Hematology, University of Verona, Verona, Italy.
University of Verona · ITUniversity of Milan · ITUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGranulocyte-colony stimulating factors (G-CSFs) are widely used to mobilize CD34 PATIENTS AND

methodsBetween 2009 and 2016, 248 patients undergoing autologous HSCT have been evaluated and divided into three groups (100 Leno-Leno, 93 Leno-Fil, 55 Fil-Fil) according to the type of G-CSF used for hematopoietic stem cell mobilization and hematopoietic stem cell recovery after transplant.

resultsThe following statistically significant differences have been observed between Leno-Leno, Leno-Fil, Fil-Fil groups: a higher number of harvested CD34

conclusionIn our experience, Lenograstim outperforms Filgrastim in terms of effectiveness and lower cost. This study shows a clinical superiority of Lenograstim over Filgrastim suggesting a potential cost savings favoring Lenograstim.

Indexed as

cost-effectivenessfilgrastimG-CSFHSCTlenograstimmobilization

Identifiers

PMID32308515
PMCPMC7135199
OpenAlexW3014729529

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.